Clinical Trial

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single center, non-randomized Phase II study enrolling Stage I-II p16+ oropharyngeal cancer patients to one of two de-escalation treatment paradigms: (1) receive surgery followed by observation or risk-adjusted adjuvant radiation (+/-chemo), or (2) individualized adaptive definitive chemoradiation (CRT).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-30; most recent amendment 2026-01-30.
Trial Details
NCT Number NCT05894083
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
Enrollment 150 participants
Start Date 2023-04-27
Primary Completion 2026-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-02